How it started
History
Avalanche Biotechnologies was founded in 2006 by Tom Chalberg, Mark Blumenkranz, Mitchell Finer, and Steven Schwartz. In 2015, a year after raising $102 million when it went public through an IPO, Chalberg stepped down as CEO following Phase IIa trial results that were labeled as "iffy".
Upon acquiring Annapurna Therapeutics and changing its name to Adverum Biotechnologies in May 2016, it also changed its ticker symbol on Nasdaq from AAVL to ADVM. In October, former Annapurna CEO Amber Salzman became CEO of Adverum.
In May 2018, Salzman left Adverum, and Chief Medical Officer Athena Countouriotis resigned after less than one year in the job. In October 2018, Leone Patterson was named the new CEO of Adverum.
In September 2019, Adverum announced six-month data from the first cohort of its phase I trial. The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation.
In 2020, Laurent Fischer replaced Patterson as CEO of Adverum. In January 2022, the FDA granted Orphan Drug Designation to Adverum's ADVM-062, developed as a single intravitreal administration for blue-cone monochromacy by delivering a functional copy of the OPN1LW gene.
From Wikipedia’s article on Avalanche Biotechnologies, shared under CC BY-SA 4.0.3